ICTM logo
STAMPEDE
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
A trial that aims to find the best treatment for people with advanced prostate cancer
What is this study about?

Prostate cancer accounts for around one fifth of all cancers among men. In the UK there are around 25,000 new cases of prostate cancer each year, and around 10,000 deaths.

Most men are given hormone therapy if their prostate cancer has spread (metastasised), or if the cancer is very likely to spread. This usually stops the tumour from growing for a while. But in most cases over time the tumour will start to grow again.

The aim of this trial is to try to prevent the tumour re-growth by adding other treatment(s) to the hormone therapy. The trial is currently using enzalutamide and abiraterone in combination with hormone therapy or, for newly diagnosed metastatic patients only, radiotherapy in combination with hormone therapy. Celecoxib, zoledronic acid, docetaxel and abiraterone alone have previously been tested.

Who is included?

Men with newly diagnosed advanced prostate cancer, or with relapsing prostate cancer.

Contact details

When is it taking place?

Now until around 2020. If new trial arms are added in the future the end date will be extended.

Where is it taking place?

Hospitals throughout the UK and Switzerland.

Who is funding the study?

The trial is mainly funded by the charity Cancer Research UK with extra support from four pharmaceutical companies: Pfizer, Sanofi-Aventis, Novartis, Janssen, Astellas and Clovis.

Further information


Type of study:
Randomised trial
Status:
Open to recruitment
Study start date:
01 October 2005
Also included in this study:
  • Health economics
  • Quality of life outcomes
  • Consumer involvement
  • NHS information centre flagging

Related Publications

Spears, M.R., James, N.D., Sydes, M.

'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial. Annals of Oncolology. 2017; 28:2327-2330

James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Parmar, M.

STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply. Lancet. 2016; 388:235-6

James, N.D., Sydes, M.R., Clarke, N.W., Ritchie, A.W., Parmar, M.

Response to 'High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice', by Tanguay et al. Clinical Oncology (Royal College of Radiologists). 2016; 28:666-7

James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., Ritchie, A.W., Parker, C.C., Russell, J.M., Attard, G., de, Bono J., Cross, W., Jones, R.J., Thalmann, G., Amos, C., Matheson, D., Millman, R., Alzouebi, M., Beesley, S., Birtle, A.J., Brock, S., Cathomas, R., Chakraborti, P., Chowdhury, S., Cook, A., Elliott, T., Gale, J., Gibbs, S., Graham, J.D., Hetherington, J., Hughes, R., Laing, R., McKinna, F., McLaren, D.B., O'Sullivan, J.M., Parikh, O., Peedell, C., Protheroe, A., Robinson, A.J., Srihari, N., Srinivasan, R., Staffurth, J., Sundar, S., Tolan, S., Tsang, D., Wagstaff, J., Parmar, M.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387:1163-1177

James, N.D., Sydes, M., Clarke, N., Mason, M.D., Parmar, .

STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply. Lancet. 2016; 388:235-236